摘要
目的总结采用以大剂量阿糖胞苷(Ara-C)为主的联合化疗方案对儿童急性白血病进行治疗的不良反应、防治措施及效果。方法 45例初诊急性白血病患儿诱导治疗达到完全缓解(CR)后予以大剂量Ara-C为主的联合巩固化疗(每次Ara-C 2.0 g/m2),观察90例次治疗中出现的不良反应及防治效果。结果所有患儿均出现明显骨髓抑制,且部分患儿出现相关感染,但对症支持治疗后获缓解;药物热、皮疹、口腔炎和结膜炎也是常见的不良反应;肝脏、肾脏、心脏及神经毒性少见。结论在大剂量Ara-C治疗过程中采用积极有效的综合防治措施,能够使患儿安全完成巩固诱导治疗。
Objective In order to understand the adverse effects of the intensive consolidation induction chemotherapy with high dose cytarabine（HDAra-C） as the main drug to treat children with acute leukemia and the results of the comprehensive prevention measures to deal with such adverse effects.Methods 45 children with acute leukemia received this intensive combined chemotherapy with HDAraC as the main drug when they reached complete remission（CR） with the induction therapy（HDAraC 2.0g/m2）.90 cases were sampled for this intensive combined consolidation therapy to observe the adverse effects and the results of the comprehensive prevention measures to treat such adverse effects.Results All the patients showed obvious bone mass suppression.Some showed infection.The drug related fever and skin rashes,are the common side effects and could be controlled with the comprehensive prevention measures,while the toxicity to the liver,kidney,heart and nerve is rare.Conclusion It indicates these adverse effects could be reduced with the comprehensive prevention measures.Therefore it is safe for children to complete this intensive consolidation induction therapy.
出处
《安徽医学》
2011年第1期38-40,共3页
Anhui Medical Journal
